# Merck (MRK) — Analyst Forecast

MRK · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/mrk/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 21 | 9 | 1 | 31 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $143.00 | $163.41 | $180.00 | 17 |

Last price $145.45 (as of Oct 13, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 12, 2026 | RBC Capital | Maintained | Sector Perform | $145.00 |
| Oct 12, 2026 | Citigroup | Maintained | Neutral | $145.00 |
| Oct 8, 2026 | Cantor Fitzgerald | Maintained | Neutral | $145.00 |
| Oct 7, 2026 | Morgan Stanley | Maintained | Overweight | $177.00 |
| Oct 5, 2026 | JP Morgan | Maintained | Overweight | $165.00 |
| Sep 29, 2026 | Scotiabank | Maintained | Sector Outperform | $180.00 |
| Sep 10, 2026 | HSBC | Maintained | Buy | $172.00 |
| Sep 9, 2026 | Leerink Partners | Maintained | Outperform | $161.00 |
| Sep 8, 2026 | Guggenheim | Maintained | Buy | $170.00 |
| Sep 4, 2026 | Wells Fargo | Maintained | Overweight | $170.00 |
| Aug 25, 2026 | Argus Research | Maintained | Buy | $170.00 |
| Aug 25, 2026 | Wolfe Research | Maintained | Outperform | $180.00 |
| Aug 21, 2026 | Goldman Sachs | Maintained | Buy | $160.00 |
| Aug 20, 2026 | Morgan Stanley | Upgraded | Equal-Weight → Overweight | $179.00 |
| Aug 20, 2026 | RBC Capital | Downgraded | Outperform → Sector Perform | $150.00 |
| Aug 20, 2026 | UBS | Maintained | Buy | $175.00 |
| Aug 20, 2026 | BMO Capital | Maintained | Outperform | $170.00 |
| Aug 12, 2026 | Daiwa Capital | Upgraded | Neutral → Outperform | $143.00 |
| Aug 11, 2026 | Argus Research | Maintained | Buy | $145.00 |
| Aug 5, 2026 | Guggenheim | Maintained | Buy | $146.00 |

## Frequently Asked Questions

### What is the price target for MRK stock?

The average 12-month analyst price target for Merck (MRK) is $163.41, with a high estimate of $180.00 and a low of $143.00, across 17 analysts.

### Is MRK a buy, sell, or hold?

Analysts covering Merck currently average a Buy rating: 21 buy, 9 hold and 1 sell, from 31 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for MRK?

The average price target of $163.41 implies 12.35% upside from the last price of $145.45.

### What is the latest analyst rating on MRK?

On Oct 12, 2026, RBC Capital maintained Merck at Sector Perform with a price target of $145.00.

## Similar Stocks

- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [GILD](https://www.lighthorse.io/tickers/gild) — Gilead Sciences, Inc. - Common Stock
- [BMY](https://www.lighthorse.io/tickers/bmy) — Bristol-Myers Squibb Company Common Stock
- [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock
- [JNJ](https://www.lighthorse.io/tickers/jnj) — Johnson & Johnson Common Stock
- [AZN](https://www.lighthorse.io/tickers/azn) — AstraZeneca PLC Ordinary Shares
- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).